LifeTech Scientific Corporation (HK:1302) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LifeTech Scientific Corporation has announced the successful completion of a one-year follow-up study for its IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System, showcasing impressive safety and effectiveness results. With a target lesion failure rate of 2.9% and zero cardiac deaths reported, the innovative scaffold is poised for CE registration approval in the European Union. This development promises significant advancements for patients with coronary heart disease worldwide.
For further insights into HK:1302 stock, check out TipRanks’ Stock Analysis page.